TW200526201A - Treating bone-related disorders with selective androgen receptor modulators - Google Patents

Abstract

The present invention provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of a bone-related disorder in a subject, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof. The present invention further provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of osteoporosis, osteopenia, increased bone resorption, bone fracture, bone frailty and/or loss of bone mineral density (BMD) in a subject, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

Description

200526201 IX. Description of the invention: [Technical field to which the invention belongs] Field of the invention The present invention relates to the prevention and treatment of bone-related disorders. In more detail, the present invention relates to a method for treating, preventing, suppressing, inhibiting, or reducing the risk of the occurrence of diseases related to scallops, such as osteoporosis, osteoporosis, an increase in linguing effects, fractures, Fragile bones and reduced bone mineral density (BMD); it is obtained by administering a therapeutically effective amount of a selective androgenic hormone regulator (SARM) compound and / or its analogue, 10 biological, Isomers, metabolites, pharmaceutically acceptable salts, agents, hydrates, N-oxides, or any combination thereof. I: First Chair] Background of the Invention It has been clearly demonstrated that bone mineral density (BMD) of both men and women decreases with age. The decrease in bone mineral content and density is related to the decrease in bone M and fracture factor. The molecular mechanism of pleiotropic sex hormones in non-reproductive tissues has just begun to be understood, but it has been clearly understood that the physiological concentrations of androgens play an important role in maintaining bone homeostasis throughout the life cycle. Therefore, when the phenomenon of androgen or 20 estrogen deficiency occurs, the rate of bone remodeling is increased accordingly, so that the balance between the dissolution and the formation effect tends to the erosion effect, resulting in a comprehensive bone loss. Shell males naturally develop androgen deficiency as they age. Androgen reduction (ADAM) in aging males refers to the reduction of mature sex hormones in 200526201 (direct reduction of androgens and lower levels of estrogen derived from the peripheral aromatization of androgens) . Androgen deficiency has also been observed in castrated men and men undergoing androgen deficiency treatment for allele cancer. 5 10 15 Androgen decreases with age. Androgen reduction in women (ADIF) refers to a gradual decrease in the production of androgens, which occurs in middle-aged women and / or in women undergoing chemotherapy and / or HIV-positive premenopausal women . In addition, different conditions may lead to a decrease in androgen, such as Addison's disease, pituitary dysfunction, and ovariectomy (removal of the ovaries). Androgen deficiency associated with ADAM, ADIF, or any of the above conditions, is related to osteoporosis-related conditions such as osteoporosis, osteoporosis, increased osteolytic function, fractures, fragility, and / or bone minerality (BMD) is associated with an increase in decreased incidence. Osteoporosis is a systemic osteoporosis disease characterized by low bone and bone tissue degradation, resulting in increased bone fragility and increased likelihood of fractures. In the United States, more than 25 million people are affected by this money, and -130 fractures are caused each year, including 500,000 spine fractures, 250,000 lame fractures, and 240,000 wrists each year. fracture. The most serious consequences of hip fractures caused by osteoporosis, 5 patients died within a year, and more than 50% of survivors became maladaptive. Older people are at the highest risk for osteoporosis, so questions will increase significantly as the population ages. Over the next sixty years, the global incidence of bone fractures is predicted to triple; and-studies estimate that in 2005, 4.5 million hip fractures will occur worldwide. Women have a higher risk of osteoporosis than men. Within five years after menopause, women's bone loss will rapidly increase. Other risk-increasing factors include: · Smoking, alcoholism, static lifestyle and low calcium intake. However, 5 men also often develop osteoporosis. Given the high incidence of osteoporosis and other bone-related disorders, bone-related disorders are also major clinical health concerns for men and women. At the basic science and clinical levels, novel approaches are urgently needed to reduce bone-related disorders such as osteoporosis, osteoporosis, increased osteolytic function, fractures, weak bones, and / or bone mineral density ( BMD). [Summary of the Invention] SUMMARY OF THE INVENTION The present invention provides a selective androgen receptor 15 modulator (SARM) compound and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable Salts, agents, hydrates, N-oxides, or any combination thereof, to provide a method for treating, preventing, suppressing, inhibiting, or reducing the incidence of a bone-related disorder in the individual. The present invention further modulates 20 (SARM) compounds and 7 or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable salts, Agents, hydrates, oxides, or any combination thereof, provided to treat, prevent, suppress, suppress or reduce osteoporosis, osteoporosis, increased osteolytic effects, fractures, and weak bones in the individual And / or one of the ways to reduce the incidence of bone mineral density (BMD) 200526201. Therefore, in a consistent embodiment, the present invention provides a method for treating an individual suffering from a disease related to scallops, the steps comprising administering to the individual a selective androgen receptor modulator compound. In another 5 embodiments, the method includes administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, agent, hydrate, or N-oxide of the SARM compound A composition. In another embodiment, the invention provides a method for preventing, suppressing, or reducing the incidence of a bone-related disorder in an individual, comprising the steps of administering a selective androgen receptor to the individual. Regulator (SARM) compounds. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical agent, hydrate, or N-oxide of the compound or any combination thereof Thing. In one embodiment, the bone-related disorder is osteoporosis. In another embodiment, the bone-related disorder is bone deficiency. In another embodiment, the ' Mayella related condition is an increase in the effect of osteolytic disease. In another embodiment, the ' 50 epiphyseal-related disorder is a fracture. In another embodiment, the bone-related disorder is a fragile bone network. In another embodiment, the bone-related disorder is a decrease in bone mineral density (BMD). In another embodiment, the osteoporosis 20 disorder is any combination of osteoporosis, osteopenia, increased osteolytic effects, fractures, bone fragility, and decreased bone mineral density (BMD). In another embodiment, the present invention provides a body for treating osteoporosis, osteoporosis, increased osteolysin effect, fractures, weak bones, and / or reduced bone mineral density (BMD). The method, whose step 200526201 includes administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, medicament, hydrate, or N-oxide of the SARM compound combination. 5 In another embodiment, the present invention provides for preventing, suppressing, inhibiting or reducing osteoporosis, osteoporosis, increased osteolytic effects, fractures, bone fragility, and bone mineral density (BMD) in one body in one body. One method of reducing morbidity involves the step of administering to the individual a selective androgenic hormone-modulating compound (SARM) compound. In another embodiment, the method 10 comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, agent, hydrate, or team oxide of a SARM compound A composition. In one embodiment, the individual is a male individual. In another embodiment, the individual is an aging male individual. In another embodiment, the 15 individuals are-castrated male individuals. In another embodiment, the individual is a male individual undergoing androgen deficiency treatment such as a prostate cancer. In another embodiment, the individual is a female individual. In another embodiment, the individual is an aging female individual. In another embodiment, the individual is a female undergoing chemotherapy! |. In another embodiment, the 20 individuals are HIV-positive premenopausal female individuals. In another embodiment, the subject is a female subject suffering from Addison's disease. In another embodiment, the individual is a female individual suffering from a pituitary dysfunction. In another embodiment, the individual is a female individual who has had its nest removed. In one embodiment, a SARM compound effective for treating, preventing, suppressing, inhibiting or reducing the incidence of a bone-related disorder 200526201 is a compound represented by the structure of Formula I:

Where G is oxygen or sulfur; X is one-bond, oxygen, CH2, NH, selenium, PR, NO or NR; T is OH, OR, -NHCOCH3 or NHCOR; Z is No2, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; Q is alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, 10 NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R, SR, SCN, NCS, OCN, NCO; or Q together with the benzene ring to which it is attached is represented by structural formula A, B or C Representative fused ring system;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or oh; and R々CH3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3; or an analog, derivative, isomer, metabolite 10 200526201, pharmaceutically acceptable salt, medicament, hydrate or N-oxide or any combination thereof of a SARM compound. In another embodiment, a SARM compound effective to treat, prevent, suppress, suppress or reduce the incidence of a bone-related disorder is one of the compounds represented by the structure of Formula 5 II:

II where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; 10 Q is alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, OSS 〇2R, S02R, SR, SCN, NCS, OCN, NCO; or Q and the benzene ring to which it is connected is a fused ring system represented by the structure A, B * c of structure 15;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or oh; or an analog, derivative, isomer of SARM compound Substances, metabolism 200526201 Substances are subject to acceptable salts, medicaments, hydrates or N_oxides or any combination thereof. 〃 In another κ; ^ case, a SARM compound that is effective in treating, preventing, suppressing, inhibiting or reducing the incidence of ganoderma-related diseases is one of the compounds represented by the structure of Chemical Formula 5 III: ^

G III

Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; G is oxygen or sulfur; R ^ CH3, CH2F, CHF2, CF3, CH2CH3 or cf2cf3; 10 τ is OH, OR, -NHCOCH3 Or NHCOR; R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or oh; A is a ring selected from the group consisting of:

12 200526201 where A and B cannot be a benzene ring at the same time; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 or SnR3;

Qi and Q2 are each independently hydrogen, alkyl, halogen, CF3, CNCR3, 5 SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR , 0S02R, S02R, SR, SCN, NCS, OCN, NCO,

10 Q3 and Q4 are each independently hydrogen, alkyl, halogen, cf3, cncr3,

SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, 〇〇〇〇2R, S02R * SR, SCN, NCS, OCN, NCO; 15 Wi is oxygen, NH, NR, NO or sulfur; and W2 is nitrogen or NO; or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, agent, hydrate, or SARM compound N-oxide or any combination thereof. 20 In another embodiment, a SARM compound effective to treat, prevent, suppress, suppress or reduce the incidence of a bone-related disorder is one of the compounds represented by the structure of Chemical Formula IV: 13 200526201 \ Τ

, CH2, NH, selenium, PR, NO or NR;

(Ri), a Q where X is a bond, oxygen G is oxygen or sulfur; T is OH, OR… NHC0CH3 or NHC0R; 5 R is alkyl, haloxyl, dihaloalkyl, tri Haloalkyl, CH #, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH; R ^ CH3, CH2F, CHF2, cf3, CH2CH3 or cf2cf3; R2 is fluorine, chlorine, bromine, iodine , CH3, CF3, OH, CN, N02, NHCOCH3, NHC0CF3, NHCOR, alkyl, arylalkyl, OR, 10 NH2, NHR, NR2, SR, SCN, NCS, OCN, NCO; R3 is fluorine, Gas, bromine, iodine, CN, N02, COR, C00H, CONHR, CF3, SnR3; or R3 and the benzene ring to which it is connected form a fused ring system represented by the following structural formula;

Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, gas, iodine, CN or SnR3; Q is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCHs, NHCOCF3, NHCOR , NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, 14 200526201

Li csrnhso2ch3, nhso2r, 0H, 〇R, 〇R, 〇C () R 0S02R, S02R, SR; or Q and the benzene ring to which it is connected-together as a fused ring represented by the structural formula A, B or C system;

5 η is an integer from 1 to 4; and m is an integer from 1 to 3; or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, agent, hydrate of a SARM compound Or N oxide or any combination thereof. 1 ° In another embodiment, a SARM compound effective to treat, prevent, suppress, suppress or reduce the incidence of a bone-related disorder is one of the compounds represented by the structure of formula V:

15 R2 is fluorine, gas, desert, moth, CH3, CF3, OH, CN, No2, NHCOCH3, NHCOCF3, NHCOR, alkyl, aryl, OR, NH2, NHR, NR2, SR; R3 is Fluorine, gas, bromine, iodine, CN, N02, COR, COOH, CONHR, CF3, S11R3; or R3 and the benzene ring to which it is connected form a condensed ring system represented by the following structure 15 200526201;

R is an alkyl group, a halogenated alkyl group, a dihalogenated alkyl group, a trihalogenated alkyl group, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or OH; 5 Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, gas, iodine, CN or SnR3; Q is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR , CONHR, NHCSCH3, NHCSCF3, 10 NHCSRNHS02CH3, NHS02R, OH, OR, COR, OCOR, OS〇2R, S〇2R, SR; or Q together with the benzene ring to which it is attached is represented by structural formula A, B or C Representative fused ring system;

η is an integer from 1 to 4; and 15 m is an integer from 1 to 3; or an analog, derivative, isomer, metabolite of a SARM compound; salts, medicaments, and hydrates that are acceptable in nature Or N-oxide or any combination thereof. In another embodiment, the compound that is effective for treating, preventing, suppressing, inhibiting or reducing the incidence of a bone-related disorder by 20% is one of the compounds represented by the structure of Chemical Formula 16 200526201 VI, or SARM Analogs, derivatives, isomers, metabolites, pharmaceutically acceptable salts, medicaments, hydrates, or N-oxides or any combination thereof of a compound.

In another embodiment, the SAM compound effective to treat, prevent, suppress, suppress or reduce the incidence of a bone-related disorder is one of the compounds represented by the structure of Chemical Formula VII, or an analog of a SARM compound, Derivatives, isomers, metabolites, pharmaceutically acceptable salts, agents, hydrates or N-oxides or any combination thereof.

In another embodiment, a SARM compound effective to treat, prevent, suppress, suppress or reduce the incidence of a bone-related disorder is one of the compounds represented by the structure of Chemical Formula VIII, or an analog or derivative of a SARM compound Compounds, isomers, metabolites, pharmaceutically acceptable salts, drugs, hydrates or N-oxides or any combination thereof.

17 200526201 t! —In the examples, an iSARM compound that is effective in treating, preventing, suppressing, inhibiting or reducing the incidence of a bone-related disorder is a compound represented by the structure of Huafeng, IX, or a compound of SARM Class = Substances, organisms, isomers, metabolites, pharmaceutically acceptable salts, gamma 5 agents, hydrates or N-oxides or any combination thereof. Regulation, music

1: In one embodiment, a 2SARM compound that is effective for treating, preventing, suppressing, inhibiting or reducing the incidence of a bone-related disorder is a compound represented by a structure with chemical structure and + X, or an analog of a SARM compound Derivatives, isomers, metabolites, pharmaceutically acceptable salts, agents, hydrates, or N-oxides, or any combination thereof, of Formula 10. ,

In the example of the 2 factory, the 2SARM compound which is effective for treating, preventing, suppressing, inhibiting or reducing the incidence of a bone-related disorder is one of the compounds represented by a chemical structure, is XI, or a class of a SARM compound. Any organism, isomer, metabolite, pharmaceutically acceptable salt, agent, hydrate, or N · oxide or any combination thereof. ^ 18 200526201

In male cases, SARM is an androgen receptor equivalent. In another example, SARM is an androgen receptor antagonist. The present invention provides a safe and effective method for treating, preventing, suppressing, suppressing or reducing the incidence of bone-related diseases; and is particularly suitable for / oral treatment of patients with bone-related diseases such as osteoporosis, osteoporosis, Male and female individuals with signs and symptoms of increased osteolytic effects, fractures, weak bones, and / or reduced bone mineral density (BMD). Brief description of the drawing 0 The present invention will be more fully understood and understood from the following detailed description and attached drawings, where: Figure 1: In female rats undergoing ovariectomy, SARM for bone minerals Content (BMC) and bone mineral density (BMD). [Embodiment 3 15 Detailed Description of Preferred Embodiments] The present invention administers a selective androgen receptor modulator (SARM) compound and / or its analogs, derivatives, isomers, metabolites to one individual. , Pharmaceutically acceptable salts, medicaments, hydrates, N-oxides, or any combination thereof, provided to treat, prevent, suppress, 20 inhibit or reduce the incidence of a bone-related disorder in the individual One way. The invention further comprises administering a selective androgen receptor modulator (SARM) compound and / or its analogs, derivatives, isomers, metabolites, 19 200526201 pharmaceutically acceptable salts, Agents, hydrates, N-oxides, or any group thereof, provided to treat, prevent, suppress, suppress, or reduce osteoporosis, osteoporosis, increased osteolytic effects, fractures, One of the five methods for the incidence of weak bones and / or reduced bone mineral density (BMD). Thus, in one embodiment, the invention provides a method for treating a subject suffering from a bone-related disorder, the steps comprising administering to the individual a selective androgen receptor modulator (SArM) compound. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, medicament, hydrate, or N-oxide of a SARM compound A composition. In another embodiment, the present invention provides a method for preventing, suppressing, inhibiting or reducing the incidence of a bone-related disorder in an individual, the steps comprising administering to the individual a selective androgen receptor modulation 15 sub (SARM) compounds. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, medicament, hydrate, or N-oxide of a SARM compound A composition. In one embodiment, the bone-related disorder is osteoporosis. In another embodiment, the bone-related disorder is bone deficiency. In another embodiment, the osteomyelitis-related disorder is an increase in osteolytic effect. In another embodiment, the bone-related disorder is a fracture. In another embodiment, the bone-related disorder is bone fragility. In another embodiment, the bone-related disorder is a decrease in monthly mineral density (BMD). In another embodiment, the osteogenesis-related disorder is any combination of osteoporosis, osteoporosis, increased osteolysin, 20 200526201 fractures, weak bones, and reduced bone mineral density (BMd). In another embodiment, the present invention provides a method for treating a subject suffering from osteoporosis, osteopenia, an increase in the role of osteolysis, a fracture, a weak bone network, and / or a decrease in bone mineral density (BMD). A method, step 5 of which comprises administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method includes administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical agent, hydrate, or N_oxide or any A composition. In another embodiment, the present invention provides a method for preventing, suppressing, inhibiting or reducing osteoporosis, osteoporosis, increased bone function, fractures, weak bones, and bone mineral density (BMD) in a body One method of reducing morbidity involves the step of administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method comprises administering a TSARM compound—analogue, derivative, isomer, 15 metabolite, pharmaceutically acceptable salt, agent, hydrate, or N-oxide or any of them combination. In one embodiment, the individual is a male individual. In another embodiment, the individual is an aging male individual. In another embodiment, the individual is a castrated male individual. In another embodiment, the individual is a male individual undergoing androgen deficiency treatment for prostate cancer. In another detailed example, the individual is a female individual. In another embodiment ' the individual is an aging female individual. In another embodiment, the individual is a female individual undergoing chemotherapy. In another embodiment, the individual is a -mv positive premenopausal individual. In another embodiment, the 21 200526201 individual is a female individual only suffering from Addison's disease. In another embodiment, the individual is a female individual suffering from a pituitary dysfunction. In another embodiment, the individual is a female individual who has had her ovaries removed. Selective androgen receptor s arm is a type of androgen 5-receptor-directed agent (ARTA), which shows a non-steroidal ligand for the androgenic and anabolic activity of the androgen receptor . These novel agents are suitable for treating a variety of hormonal-related conditions in men, including a) male contraceptive effects; b) treating a variety of hormonal-related conditions, such as those associated with androgen reduction (ADAM) in aging men1 〇 Conditions such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, muscular anemia, osteoporosis, benign prostatic hypertrophy, mood and Cognitive changes and prostate cancer; c) Treatment of conditions associated with ADIF, such as sexual dysfunction, decreased libido, hypogonadism, muscular dysfunction, 15-month shellfish deficiency, osteoporosis, mood and cognitive changes, depression Disease, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of acute and / or chronic muscle wasting conditions; prevention and / or treatment of dry eye conditions 〇 Oral androgen replacement therapy, and / or g) reduce the incidence of prostate cancer, curb prostate cancer or cause prostate cancer to shrink phenomenon. In the κ example, a SARM compound that is effective in treating, preventing, suppressing, inhibiting or reducing the incidence of a bone-related disorder is one of the compounds represented by the chemical structure of the compound. 22 200526201

Where G is oxygen or sulfur; X is one-bond, oxygen, CH2, NH, selenium, PR, NO or NR; T is OH, OR, -NHCOCH3 or NHCOR; 5 Z is N02, CN, COOH, COR, NHCOR Or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; Q is alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, 10 NHS02R, OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS, OCN, NCO; or Q together with the benzene ring to which it is attached is represented by structural formula A, B or C Representative fused ring system;

R is alkyl, haloalkyl, dihalo, trihalo, CH2F, 15 CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or 0H; and RACH3, CH2F, chf2, cf3 , Ch2ch3, or cf2cf3. In one embodiment, SARM is an analog of a compound of formula I. In another embodiment, SARM is a derivative of a compound of formula I. In another embodiment, SARM is one of the compounds of formula I 23 200526201 isomer. In another embodiment, SARM is a metabolite of a compound of formula I. In another embodiment, SARM is a pharmaceutically acceptable salt of a compound of Formula I. In another embodiment, SARM is a pharmaceutical agent of a compound of formula I. In another embodiment, SArm is a hydrate of a compound of formula 1. In another embodiment, SARM is an N-oxide of one of the compounds of Formula I. In another embodiment, SARM is one of the analogs, derivatives, metabolites, isomers, pharmaceutically acceptable salts, agents, hydrates or N-oxides of a compound of formula I One composition. 10 In one embodiment, the SARM compound is a compound of formula I, wherein X is oxygen. In another embodiment, the SARM compound is a compound of Formula I, wherein G is oxygen. In another embodiment, the SARM compound is a compound of Formula I, wherein Z is No. In another embodiment, the SARM compound is a compound of formula I, wherein z is cn. 15 In another embodiment, the SARM compound is a compound of formula I, wherein Y is CF3. In another embodiment, the SARM compound is a compound having a chemical formula, wherein Q is NHCOCH3. In another embodiment, the Sarm compound is a compound of formula I, wherein Q is fluorine. In another embodiment, the SARM compound is a compound of Formula I, where T is 0H. 20 In another embodiment, the SARM compound is a compound of Formula I, wherein R ^ CH3. In another embodiment, the SARM compound is effective to treat, prevent, suppress, inhibit or reduce the incidence of a bone-related disorder , Is a compound represented by the structure with chemical gas II: 24 200526201

Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 Or SnR3; Q is alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R SR, SCN, NCS, OCN, NCO; or Q and the benzene ring to which it is connected is a fused ring system represented by the structure 10, A, B or C;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, Ch2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or OH. In one embodiment, SARM is an analog of one of the compounds of formula II. In another embodiment, SARM is a derivative of a compound of formula II. In another embodiment, SARM is an isomer of a compound of formula II. In another embodiment, SARM is a metabolite of a compound of formula II. In another embodiment, SARM is a pharmaceutically acceptable salt of a compound of formula η. In another embodiment, SARM is a pharmaceutical agent having a compound of formula II. In another embodiment, SARM is a hydrate of a compound of formula II. In another embodiment, sarm is an N-oxide, a compound of formula II. In another embodiment, SARM is an analog, derivative, metabolite, isomer 5 One of the compositions. In one embodiment, the SARM compound is a compound of Formula II 'wherein X is oxygen. In another embodiment, the SARM compound is a compound of formula II, wherein Z is n02. In another embodiment, the SARM 10 compound is a compound of Formula II, wherein Z is CN. In another embodiment, the SARM compound is a compound of formula II, wherein γ is CF3. In another embodiment, the saRM compound is a compound of formula II, wherein q is NHCOCH3. In another embodiment, the SARM compound is a compound of formula II, wherein Q is fluorine. 15 In another embodiment, a SARM compound effective to treat, prevent, suppress, suppress or reduce the incidence of a bone-related disorder is one of the compounds represented by the structure of formula III:

Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; 20G is oxygen or sulfur; RACH3, CH2F, chf2, CF3, CH2CH3 or CF2CF3; T is OH, OR, -NHC0CH3 or NHCOR; 26 200526201 R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH; A is a ring selected from the group consisting of :

5 B is a ring selected from the group:

Where A and B cannot be a benzene ring at the same time; Z is No. 02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; 10 (^ and ( 52 are each independently hydrogen, alkyl, halogen, CF3, CNCR3,

SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R, SR, SCN, NCS, OCN, NCO,

Q3 and Q4 are each independently hydrogen, alkyl, halogen, cf3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, 27 200526201, COOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, c 〇R, 〇COR, 〇〇2r, S02R or SR, SCN, NCS, OCN, NCO;

Wi is oxygen, NH, NR, NO or sulfur; and 5 W2 is nitrogen or NO. In one embodiment, SARM is an analog of a compound of formula ill. In another embodiment, SARM is a derivative of a compound of formula III. In another embodiment, SARM is an isomer of a compound of formula III. In another embodiment, SARM is a metabolite of a compound of formula III. In another embodiment, SARM is a pharmaceutically acceptable salt of a compound of Formula III. In another embodiment, SARM is an agent of a compound of formula III. In another embodiment, SARM is a hydrate of a compound of formula III. In another embodiment, SARM is an N-oxide, a compound of formula III. In another embodiment, SARM is any one of an analog, derivative, metabolite, isomer, pharmaceutically acceptable salt, agent, hydrate or N-oxide of a compound of formula One of the compositions. In one embodiment, the SARM compound is a compound having the formula in, where X is oxygen. In another embodiment, the SARM compound is a compound of formula IV, wherein G is oxygen. In another embodiment, the SARM compound is a compound of formula IV, wherein T is OH. In another embodiment, the SARM compound is a compound of formula III, wherein 仏 is CH3. In another embodiment, the SARM compound is a compound of Formula III, wherein Z is NO2. In another embodiment, the SARM compound is a compound of formula 28 200526201, wherein Z is CN. In another embodiment, the SARM compound is a compound of Formula III, wherein Y is CF3. In another embodiment, the SARM compound is a compound of formula III 'wherein Qi is NHCOCH3. In another embodiment, the SARM compound is a compound of Formula 5 III, wherein it is fluorine. The substituents Z and Y may be located at any position in a ring having these substituents (hereinafter referred to as "A ring"). In one embodiment, the substituent Z is in the para position of the A ring. In another embodiment, the substituent Y is located at the meta position of the A ring. In another embodiment, the substituent Z is in the para position of the A ring, and the substituent Y is in the meta position of the A ring. The substituents 仏 and 仏 may be located at any position in the ring having these substituents (hereinafter referred to as the "B ring"). In one embodiment, the substituent 仏 is located in the para position of the b ring. In another embodiment, the substituent VII is hydrogen. In another embodiment, the substituent 仏 is located in the para position of the B ring, and the substituent q2 is hydrogen. In another embodiment, the substituent Q2 is hydrogen. In another embodiment, the substituent 仏 is NHCOCH3 and is located in the para position of the B ring, and the substituent q2 is hydrogen. In another embodiment, a SARM compound effective to treat, prevent, suppress, suppress or reduce the incidence of a bone-related disorder is one of the compounds represented by the structure of formula IV:

Where X is a bond, oxygen, CH, cis, shixi, pR, NO or NR; 29 200526201 G is oxygen or sulfur; T is OH, OR, -NHCOCH3 or NHCOR; R is alkyl, haloalkyl, di Haloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or OH; 5 RACH3, CH2F, CHF2, CF3, CH2CH3, or cf2cf3; R2 is fluorine, gas, desert, or hafnium , CH3, CF3, OH, CN, N02, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR, SCN, NCS, OCN, NCO;

R3 is fluorine, gas, bromine, ethene, CN, N02, COR, COOH, CONHR, 10 CF3, S11R3; or R3 and the benzene ring connected to it form a condensed ring system represented by the following structure;

Z is N02, CN, COR, COOH or CONHR;

Y is CF3, Fluorine, Mo, Qi, E, CN, or SnR3; 15 Q is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHC0CF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OH, OR, COR, OCOR, 0S02R, S02R, SR; or Q and the benzene ring connected to it, starting from a fused ring system represented by 20 structural formula A, B or C ;

200526201 η is an integer from 1 to 4; and m is an integer from 1 to 3. In one embodiment, SARM is an analog of a compound of formula IV. In another embodiment, SARM is a 5-derivative of a compound of formula IV. In another embodiment, SARM is an isomer of a compound of formula IV. In another embodiment, SARM is a metabolite of a compound of Formula IV. In another embodiment, SARM is a pharmaceutically acceptable salt of a compound of Formula IV. In another embodiment, SARM is an agent of a compound of formula IV. In another embodiment 10, SARM is a hydrate of a compound of formula IV. In another embodiment, SARM is an N-oxide, a compound of formula IV. In another embodiment, SARM is any one of the analogs, derivatives, metabolites, isomers, pharmaceutically acceptable salts, agents, hydrates or N-oxides of a compound of formula IV One composition. 15 In one embodiment, the SARM compound is a compound of formula IV, wherein X is oxygen. In another embodiment, the SARM compound is a compound of formula IV, wherein G is oxygen. In another embodiment, the SARM compound is a compound of formula IV, wherein Z is NO2. In another embodiment, the SARM compound is a compound of formula IV, wherein Z is 20 CN. In another embodiment, the SARM compound is a compound of formula IV, wherein Y is CF3. In another embodiment, the SARM compound is a compound of formula IV, wherein Q is NHCOCH3. In another embodiment, the SARM compound is a compound of formula IV, wherein Q is fluorine. In another embodiment, the SARM compound is a compound 31 200526201 of formula IV, wherein T is OH. In another embodiment, the SARM compound is a compound having Chemical Formula IV, and its center is (: 113. In another embodiment, the SARM compound is a compound having Chemical Formula IV, where Q is fluorine and R2 is CH3. In another embodiment, the SARM compound is a compound 5 of formula IV, wherein Q is fluorine and R2 is gas. The substituents Z, Y, and R3 may be located in a ring having such substituents (hereinafter referred to as "A Ring "). In one embodiment, the substituent 2 is located in the para position of the A ring. In another embodiment, the substituent γ is located in the meta position of the A ring. In another embodiment The Z substituent is located in the para position of the A ring, and the Y substituent 10 is located in the meta position of the A ring. The substituents Q and 2 may be located in a ring having such substituents (hereinafter referred to as "B ring"). At any position. In one embodiment, the substituent Q is in the para position of the B ring. In another embodiment, the substituent Q is in the para position of the B ring. In another embodiment, the substituent is (^ 1 is) ^ 11: 0: 0 :: 113 and the para position of ring B. 15 As expected here, when the integers m and η are greater than 1, the substituent is And R3 are not limited to the special substituent, and may be any combination of the above substituents. In another embodiment, a 2SARM compound effective to treat, prevent, suppress, inhibit or reduce the incidence of a bone-related disorder One of the compounds represented by the structure of Chemical Formula V:

20 γ of which 32 200526201 R2 is fluorine, gas, bromine, hydrogen, CH3, CF3, OH, CN, No2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR R3 is fluorine, chlorine, bromine, carbon, CN, N02, COR, COOH, CONHR, 5 CF3, SnR3; or R3 and the benzene ring connected to it form a condensed ring system represented by the following structural formula;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or oh; Z is N02, CN, COR, COOH, or CONHR; Y CF3, rat, bromine, gas, moth, CN or S11R3; Q is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, 15 NHCSRNHS02CH3, NHS02R, OH, OR, COR, OCOR, OS〇2R, S〇2R, SR; or Q and the benzene ring to which it is connected is a fused ring system represented by the structural formula A, B or C;

η is an integer from 1 to 4; and η is an integer from 1 to 3. 33 200526201 In one embodiment, SARM is an analog of a compound of formula V. In another embodiment, SARM is a derivative of a compound of formula V. In another embodiment, SARM is an isomer of a compound of formula V. In another embodiment, SARM is a 5-metabolite of a compound of formula V. In another embodiment, SARM is a pharmaceutically acceptable salt of a compound of formula v. In another embodiment, SARM is an agent of a compound of formula V. In another embodiment, SARM is a hydrate of a compound of formula V. In another embodiment, SARM is an N-oxide, a compound of formula V. In another embodiment, SARM 10 is one of the analogs, derivatives, metabolites, isomers, pharmaceutically acceptable salts, agents, hydrates, or N-oxides of a compound of formula V One of the compositions. In another embodiment, SARM is a compound of formula V, wherein Z is NO2. In another embodiment, SARM is a compound of formula V, where Z is CN. In another embodiment, SARM is a compound of formula V, wherein Y is CF3. In another embodiment, SARM is a compound of formula V, wherein q is nhcoch3. In another embodiment, 'SARM is a compound of formula v, wherein Q is fluorine. In another embodiment, SARM is a compound of formula V, wherein Q is fluorine and 20 is converted to ^^ 3. In another embodiment, SARM is a compound of formula V, where Q is fluorine and R2 is gas. As discussed in the above compound IV, the substituents Z, y, and ^ may be located at any position in the a ring, and (^ and the heart may be at any position in the 5 ring. Furthermore, as described above, when the integer m and When n is greater than 1, the substituent R3 and R3 are not limited to the substituent of a specific 34 200526201 and may be any combination of the above substituents. In another embodiment, effective treatment, prevention, suppression, and lower correlation The incidence of disease iSARM compounds are represented by structures with: vi-compounds.

Like. In another embodiment, SARM is a derivative of a compound having a chemical formula. In another embodiment, SARM is an isomer-isomer of chemical formula Vl. In another embodiment, the slave surface is a chemical gas dagger. 10 metabolite of a compound. In another embodiment, the compound is considered to be: a pharmaceutically acceptable salt of a compound of VI. In another embodiment, the formula SARM is a pharmaceutical agent of the compound of formula VI. In other embodiments, SARM is a hydrate of a compound of formula vi. In two embodiments, SARM is one of the compounds of formula VI. N oxide ~ lean 15. In another embodiment, SARM is of compound of formula ... ~. A composition of any one of pharmaceutically acceptable salts, hydrates, or N-oxides. In another embodiment, the drug is effective to treat, prevent, suppress, and reduce bone mass Incidence of the disease iSARM compound, which is one of the compounds represented by the structure with a chemical formula = 2〇VII. Formula 35 200526201

In one embodiment, SARM is an analog of a compound of formula VII. In another embodiment, SARM is a derivative of a compound of formula VII. In another embodiment, SARM is an isomer of a compound of Formula VII. In another embodiment, SARM is a metabolite of a compound of formula VII. In another embodiment, SARM is a pharmaceutically acceptable salt of a compound of formula VII. In another embodiment, SARM is an agent of a compound of formula VII. In another embodiment, SARM is a hydrate of a compound of formula VII. In another embodiment, SARM is an N-oxide of a compound of formula VII. In another embodiment, SARM is one of the analogs, derivatives, metabolites, isomers, pharmaceutically acceptable salts, agents, hydrates or N-oxides of a compound of formula VII One composition. In another embodiment, a SARM compound effective to treat, prevent, suppress, inhibit or reduce the incidence of a bone-related disorder is one of the compounds represented by the structure of Formula VIII.

In one embodiment, SARM is an analog of a compound of formula VIII. In another embodiment, SARM is a derivative of the compound of formula VIII. In another embodiment, SARM is an isomer of a compound of formula VIII. In another embodiment, SARM is a metabolite of a compound of Formula VIII. In another embodiment, SARM is a pharmaceutically acceptable salt of a compound of formula VIII. In another embodiment, 5 SARM is an agent of a compound of formula VIII. In another embodiment, SARM is a hydrate of a compound of formula VIII. In another embodiment, SARM is an N-oxide, a compound of formula VIII. In another embodiment, SARM is one of the analogs, derivatives, metabolites, isomers, pharmaceutically acceptable salts, drugs, hydrates, or N-oxides of a compound of formula VIII. One of the compositions. In another embodiment, the SARM compound effective to treat, prevent, suppress, suppress or reduce the incidence of a bone-related disorder is one of the compounds represented by the structure of Formula IX.

15 In one embodiment, SARM is an analog of a compound of formula IX. In another embodiment, SARM is a derivative of a compound of formula IX. In another embodiment, SARM is an isomer of a compound of formula IX. In another embodiment, SARM is a metabolite of a compound of formula IX. In another embodiment, SARM is a pharmaceutically acceptable salt of one of the compounds of formula IX20. In another embodiment, SARM is an agent of a compound of formula IX. In another embodiment 37 200526201, SARM is a hydrate of a compound of formula IX. In another embodiment, SARM is an N-oxide, a compound of formula IX. In another embodiment, SARM is one of the analogs, derivatives, metabolites, isomers, pharmaceutically acceptable salts, drugs, hydrates, or N-oxides of a compound of formula IX. One of the compositions. In another embodiment, a SARM compound effective to treat, prevent, suppress, suppress or reduce the incidence of a bone-related disorder is one of the compounds represented by the structure of Chemical Formula X.

10 In one embodiment, SARM is an analog of a compound of formula X. In another embodiment, SARM is a derivative of a compound of formula X. In another embodiment, SARM is an isomer of a compound of formula X. In another embodiment, SARM is a metabolite of a compound of formula X. In another embodiment, SARM is one of the pharmaceutically acceptable salts of compound 15 of formula X. In another embodiment, SARM is an agent of a compound of formula X. In another embodiment, SARM is a hydrate of a compound of formula X. In another embodiment, SARM is an N-oxide, a compound of formula X. In another embodiment, SARM is one of the analogs, derivatives, metabolites, isomers, pharmaceutically acceptable salts, agents, hydrates, or N-oxides of a compound of formula X One of the compositions. 38 200526201 In another embodiment, a SARM compound effective to treat, prevent, suppress, suppress or reduce the incidence of a bone-related disorder is one of the compounds represented by the structure of Chemical Formula XI.

5 In one embodiment, SARM is an analog of a compound of formula XI. In another embodiment, SARM is a derivative of a compound of formula XI. In another embodiment, SARM is an isomer of a compound of formula XI. In another embodiment, SARM is a metabolite of a compound of formula XI. In another embodiment, SARM is a pharmaceutically acceptable salt of a compound of Formula 10 XI. In another embodiment, SARM is an agent of a compound of formula XI. In another embodiment, SARM is a hydrate of a compound of formula XI. In another embodiment, SARM is an N-oxide, a compound of formula XI. In another embodiment, SARM is one of the compounds of formula XI, which is similar to any of 15 compounds, derivatives, metabolites, isomers, pharmaceutically acceptable salts, agents, hydrates, or N-oxides. One of the compositions. The substituent R in compounds VII and (II) is defined herein as alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, element, alkenyl or OH. 20 "Alkyl" means a saturated aliphatic hydrocarbon, including straight-chain, branched-chain and cyclic alkyl. In one embodiment, the alkyl group has 1 to 12 carbons. In another embodiment, the alkyl group has 1 to 7 carbons. In another embodiment, the alkane 39 200526201 group has 1 to 6 carbons. In another embodiment, the alkyl group has 1 to 4 carbons. The alkyl group may be unsubstituted, or substituted by one or more groups selected from the group consisting of: 1,2, 3, 3, 3, 4 , Zoyl, Amine, Alkenylamino, Dialkylamino, Junki, 5thio and thioalkyl. "Alkenyl" refers to an unsaturated hydrocarbon that includes linear, branched, and cyclic groups having one or more double bonds. An alkenyl group may have one double bond, two double bonds, three double bonds, and the like. Examples of alkenyl are vinyl, propenyl, butenyl, cyclohexenyl and the like. The alkenyl group may be unsubstituted, or substituted with one or more groups selected from the group 10: halogen, triphenyl group, oxo group, fluorenyl group, fluorenyl group, dioxo group Group, nitro group, amino group, alkyl group, dialkyl group, carboxyl group, thio group, and thioalkyl group. "Haloalkyl" means an alkyl group, as defined above, which is substituted by one or more halogen atoms, such as by fluorine, gas, bromine or iodine. 15 "Aryl" means an aromatic group having at least one carbocyclic or heterocyclic aromatic group; it may be unsubstituted or substituted with one or more groups selected from the group consisting of: , Alkoxycarbonyl, amido, alkyl, amido, dialkyl, ammonium, amine, alkyl, dialkyl, carboxy or thio or thioalkyl. Non-limiting examples of aryl rings are benzene20, naphthyl, π-pyranyl, σ-pyridyl, 0-ratio. Qin Ji, Ding Ji ,. Compared with Jun base, outer stilbyl, succinyl, phenylthio, sulphydryl, stilbyl, isoxalyl, etc. "Hydroxy" refers to an oxo group. "Alkenyl" refers to a group having at least one carbon-carbon double bond. The i-generation group means fluorine, chlorine, bromine or iodine. "Arylalkyl" means an alkyl group bonded to an aryl group, wherein alkyl 40 200526201 and aryl are as defined above. An example of an arylalkyl group is an f group. As expected herein, the present invention relates to a SARM compound and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable salts, pharmaceuticals, hydrates, N-oxides or Use of the composition for treating / preventing 5 bone-related disorders. Thus, in one embodiment, the method of the present invention includes administering an analog of SARM. In another embodiment, the method of the invention comprises administering a derivative of SARM. In another embodiment, the method of the invention comprises administering an isomer of SARM. In another embodiment, the method of the invention comprises administering a metabolite to SARM. In another embodiment, the method of the invention includes administering a pharmaceutically acceptable salt of SARM. In another embodiment, the method of the invention comprises administering a medicament to SARM. In another embodiment, the method of the invention comprises administering a monohydrate of SARM. In another embodiment, the method of the invention comprises administering a N-oxide to SARM. In another embodiment, the method of the present invention comprises administering any of a class of 15 analogs, derivatives, isomers, metabolites, pharmaceutically acceptable salts, agents, hydrates, or N-oxides of SARM A composition. As defined herein, the term "" isomers "includes, but is not limited to, optical isomers and analogs, structural isomers and analogs, configuration isomers and analogs, and the like. In the examples, the present invention covers the use of different optical isomers of SARM compounds. Skilled artisans will understand that the present invention contains at least one chiral center. Therefore, the SARM used in the method of the present invention may Exists and separates in optically active or racemic forms. Some compounds may also exist in polymorphic forms. It should be understood that the invention encompasses any racemic, optical 41 200526201 cyclic, polymorphic or stereoisomeric forms or forms thereof. In the embodiment of the sex-suitable formula, SArma: is a prime-related condition. At ― 5 10 15 20 ― it is pure (s) ^ l ⑻-isomer. In another embodiment, and (_ Do n’t ==. In another embodiment, '8 Gu is an equal amount of ⑻ and ⑻_1 in another implementation, s_ is included to include how to prepare an optical racemic mixture. Segregation of forms ?: = by recrystallization technique ... by, by chiral synthesis (B) The synthesis of the starting compound is used for chromatographic analysis and separation.) Or, by using a chiral stationary phase, including the amino group-substituted citric acid and hydrochloric acid, , Machine texts such as L ,, _, acceptable salts on 柰 子 ,,. The present invention also mentions the treatment of & oxide of a di-substituted compound with sodium oxide. At the same time, the compound # 1 is used to prepare pharmaceutically acceptable salts of aliphatic and aromatic buttons. ^ ^ Advances include derivatives of SAR] y ^ b complexes. "Derivatives" ~ 5 daggers < Not limited to derivatives, acid derivatives, amidine derivatives, amidines, etc. & The present invention further includes hydrates of SARM compounds. The term hydrate includes, but is not limited to, hemihydrate, monohydrate, dihydrate, trihydrate, and the like. -This hair improvement includes metabolites of SARM compounds. "The term metabolite," means any substance produced by another substance through metabolic action or metabolic methods. 42 200526201 The present invention further includes a medicament for a SARM compound. "Pharmaceutical," means the term applies to A composition of one of the defined pharmaceutical uses (the pharmaceutical composition is as intended herein), the SARM compound of the present invention is suitable for treating, preventing, suppressing, inhibiting or reducing the incidence of a bone-related disorder 5 in a body, for example Osteoporosis, osteoporosis, increased osteolytic effects, fractures, weak bones, and / or reduced bone mineral density (BMD). As defined herein, "osteoporosis" refers to a reduction in bone calcification or density. The term covers all skeletal systems that are aware of the condition. The term "osteoporosis" refers to the thinning of bone and the reduction of bone mass by about 10 and the depletion of bone protein. Osteoporosis is a systemic bone Disease, which is characterized by low bone quality and bone tissue deterioration, and thus increases bone fragility and the possibility of fractures. Bone in patients with osteoporosis The degree of abnormality increases the risk of fracture. Osteoporosis depletes the calcium and protein collagen normally seen in the bone, resulting in abnormal bone quality or reduced bone density of 15 degrees. Bones with osteoporosis generally do not cause fractures Fractures may occur in the event of a minor fall or injury. Fractures can be in the form of fissures (as in the case of hip fractures) or collapses (as in the case of spinal compression fractures). The spine, hips, and wrists are Common sites of osteoporotic fractures, although fractures may also occur in other skeletal sites. Osteoporosis that is not suppressed by 20 may lead to changes in posture, physiological abnormalities, and decreased mobility. "Bone mineral density (BMD ") Is the calculation after actual bone mass measurement. The absolute amount of bone measured by bone mineral density (BMD) is generally related to the strength of the bone and its ability to bear weight. By measuring BMD 43 200526201 may predict the risk of fracture in the same way that blood pressure is measured to help predict the risk of stroke. In one embodiment, the Bone mineral content mapping technology to measure BMD. Bone density of hip, spine, wrist or 5 calcaneus can be measured by a variety of techniques. The preferred BMD measurement method is dual energy X-ray density measurement (DXA). Use this technique to measure the BMD of the hip, abdomen (AP) spine, lateral spine, and wrist. Measurements at any site predict overall fracture risk, but information from a particular site is the best prediction of a fracture at that site Factor. Quantitative computerized tomography (QCT) can also be used to measure the BMD of the spine. See Wahner HW, Dunn WL, Thorsen HC, et al. "Nuclear Medicine · Quantitative Procedures," Book B, Published by Toronto Little, Brown & Co. in 1983 (see pages 107-132). An article entitled "Analysis of Bone Minerals, Part I," was published in the Journal of Nuclear Medicine, pages 1134-1141 (1984). Another 15 articles were titled "Radial The article on bone mineral density was published in the Journal of Nuclear Medicine, Issue 26, No. 11 (1985), pages 13-39. A summary of the use of the 7 cameras in measuring bone mineral content is ⑻S. Hoory et al. In Radiology 157 (P), p. 87 (1985) B. and (b) c · R wils〇n et al. In Radi〇gy 20, 157 (p), p. 88 (1985). The term "osteolytic effect", as defined herein, refers to the loss of moonshells due to osteoclasting. The human bone network undergoes a dynamic renewal process from time to time, which includes osteolytic effects and osteogenesis. Osteolysis is based on the destructive effects of osteoclasts on moon-based osteoclasts. Most of the osteoclastic disorders are caused by bone formation44 200526201 The balance between the effects of osteolysis and osteolytic money is disturbed. During the continuous plastic process, if new bone The formation effect is relatively less than the osteolytic effect of osteoporosis. "The increase in osteolytic effect," the term, refers to bone formation = the balance between osteolytic effect and osteolytic effect is biased toward osteolytic effect. 5 The term “fracture,” as defined herein, refers to the fracture of the bone path, and the vertebral and non-vertebral fractures of the Erhan Temple on the same day. The “fragility of the bone network” as defined herein refers to the bone. Weakened state, which is the prime cause of such bone fractures. In one embodiment, the system-administered SARM compound of the present invention is an aging individual, such as a male face or a female body. ^ "Old Π" as defined herein refers to the process of aging. In the case of the bee, the age of the aging system is more than 40 years old. In the case of the bee example, the age of the aging system is more than 45 years. In another example, a body with an age of more than 50 years in the aging system. In another example, the one with an age of more than 55 years in the aging system. In the 15 other cases, , The aging individual is more than 60 years old. In another example, the aging individual is more than 65 years old. In another embodiment, the aging individual is more than 70 years old. Individuals. In another embodiment, the aging system is one body. As expected herein, the SARM compounds of the present invention can be divided into several subgroups based on their biological activity. For example, several The sarm compound has a potent effect on muscle or bone. Other 58-centimeter compounds have an antagonistic effect on muscle or bone. The SARM compound of the present invention is a novel type of androgen-targeted agent (ARTA). Show a non-class Alcohol ligands have androgenic or anti-androgenic and anabolic activity in andro45 200526201 sex hormone receptors. These agents define a novel subtype of drugs, which are selective androgen receptor regulators ( SARM). Androgen receptor (AR) is a ligand-activated transcription regulator protein 5 white matter, which regulates the development of male sexual characteristics and functions through its activity and endogenous male hormones (male hormones). Action. Androgen hormones are steroids made from testes and adrenal cortex in the body. Androgen steroids play an important role in many physiological functions, including male sexual characteristics such as muscle and bone, prostate growth, spermatogenesis, and males Development and Maintenance of Hair State 10 (Matsumoto in Endocrinol. Met · Clin · N · Am No. 23 pp. 857-75 (1994) E). Endogenous steroid-type androgens include testosterone and dihydrotestosterone ( "DHT"). Other steroidal androgens include esters of testosterone, such as valproate, propionate, phenylpropionate, cyclopentylpropionate Esters, isocaproates, heptanoates and caprates, and 15 other synthetic male hormones such as 7-methyl-desterosterone ("MENT") and its acetates (Sundaram et al. In Ann · Med. · "7-Methyl-normethylsterone (" MENT "), 25th issue, 199-205 (1993). Best male hormones for contraception in men, B (" Sundaram, "). Receptor synergist is a substance that binds to the receptor and activates them. 20 Receptor part synergist is a substance that binds to the receptor and activates them. The receptor antagonist is related to the receptor. A substance that binds and deactivates them. As shown herein, the SARM compounds of the present invention have a tissue-selective effect, wherein depending on the tissue, an agent may be a synergist, a partial synergist, and / or an antagonist. For example, SARM compounds can stimulate muscle tissue, 46 200526201 and simultaneously inhibit prostate tissue. In one embodiment, it is suitable for treating and preventing bone-related disorders, and thus suitable for combining with AR and activating it. In another embodiment, a SARM suitable for treating and preventing a bone-related disorder is an AR antagonist, and is therefore suitable for binding to and deactivating ar 5. Analytical methods for determining whether a compound of the present invention is an AR synergist or antagonist are well known to those skilled in the art. For example, AR synergistic activity can be determined by monitoring the SARM compound to maintain and / or stimulate the growth of ar-containing tissues such as the prostate and seminal vesicles, such as by measuring weight. AR antagonist activity can be determined by monitoring the SARM compound's inhibition of growth of AR-containing tissue 10 '. In another embodiment, the SARM compounds of the invention can be classified as partial AR synergists / antagonists. These SARMs are gAR synergists in some tissues, resulting in increased transcription of AR-responsive genes (such as muscle and anabolic effects). In other tissues, these compounds act as competitive inhibitors of 15steroids / DHT on AR to prevent the inherent androgenic effect of androgens. The SARM compounds of the present invention bind to androgen receptors in a reversible or irreversible manner. In one embodiment, the SARM compound is bound to the androgen receptor in a reversible manner. In another embodiment, the SARM compound is bound to the androgen receptor in an irreversible manner. The compound of the present invention may contain an official moiety (affinity labeling) 'to allow the thiolation of the androgen receptor (i.e., covalent bond formation). Therefore, in this case, the compound binds to the receptor in an irreversible manner, and thus cannot be replaced by a steroid such as the endogenous ligands DHT and testosterone. 47 200526201 Musical composition as used herein "" pharmaceutical composition "means a" therapeutically effective amount "of the active ingredient, that is, a SARM compound, and a pharmaceutically acceptable carrier or diluent. The "therapeutically effective amount" means that for a specific condition 5 and the course of administration, the amount provides a therapeutic effect. The pharmaceutical composition containing a tincture agent can be administered to a subject by any method known to skilled artisans, such as a parenteral method, a near cancer method, a transmucosal method, a transdermal method, an intramuscular method, a vein Internal, intradermal, subcutaneous, intraperitoneal, intracardiac, intracranial, 10 intravaginal or intratumoral. In one embodiment, the pharmaceutical composition is administered orally, and is thus formulated in a form suitable for oral administration, such as a solid or liquid formulation. Suitable solid oral formulations include lozenges, capsules, pills, granules, pills, and the like. Suitable liquid oral formulations include solutions, suspensions, 15 emulsions, emulsions, oils and the like. In one embodiment of the invention, the SARM compound is formulated into a capsule. According to this embodiment, the composition of the present invention contains a hard gelatin capsule in addition to the SARM active compound and an inert carrier or diluent. Furthermore, in another embodiment, the pharmaceutical composition is administered by intravenous, intra-arterial or intramuscular injection of a liquid preparation. Suitable liquid formulations include solutions, suspensions, emulsions, emulsions, oils and the like. In one embodiment, the pharmaceutical composition is administered intravenously, and is thus formulated in a form suitable for intravenous administration. In another embodiment, the pharmaceutical composition is administered intra-arterially, and is thus formulated in a form suitable for intra-arterial administration 48 200526201. In another embodiment, the pharmaceutical composition is administered intramuscularly, and is thus formulated as an open-ended type suitable for intramuscular administration. Furthermore, in another embodiment, the pharmaceutical composition is administered topically to the surface of the body, and is thus formulated in a form suitable for topical administration. 5 Suitable topical formulations include Ningsheng, ointment, emulsion, cream, lotion, drops and so on. For topical administration, the SARM agent or a physiologically acceptable derivative thereof such as salts, vinegars, N_oxides, etc. is prepared in a pharmaceutically acceptable manner with or without a pharmaceutical carrier In the form of a solution, suspension or emulsion in a diluent and applied. 10 Furthermore, in another embodiment, the pharmaceutical composition is administered as a suppository, such as a rectal suppository or a urethral suppository. Furthermore, in another embodiment, the «Haiwanyu composition is administered by implanting a pill subcutaneously. In another embodiment, the bolus provides a controlled release of the SARM agent over a period of time. In another embodiment, the active compound may be delivered in a carrier, 15 particularly a liposome (see Langer in Science 249, 1527-1533 (1990) e text; Treat et al. In Lopez-Berestein Liposomes in Infectious Diseases and Cancer Therapy, edited with Fidler, Book B, pp. 353-365, published by Liss in the two countries, Ugly, U.S. and Sc in 1989; aforementioned Lopez-Berestein B, Book 317 -327 pages; see the same book as a whole). 2 "A pharmaceutically acceptable carrier or diluent, as used herein, is well known to those skilled in the art. The carrier or diluent may be a centering agent or diluent used in solid formulations; Liquid carriers or diluents in liquid formulations; or mixtures thereof. Solid carriers / diluents include, but are not limited to, a gum, a starch (corn 49 200526201 starch, pregelatinized starch), and a sugar (lactose, mannose). Alcohol, sucrose, dextrose), a cellulosic substance (such as microcrystalline cellulose), an acrylate (such as polymethacrylate), calcium carbonate, magnesium oxide, talc or mixtures thereof. For liquid formulations, Pharmaceutically acceptable carriers can be aqueous or non-aqueous solutions, suspensions, emulsions, or oils. Examples of non-ice solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate. Aqueous Carriers include water; alcohols / aqueous solutions; emulsions or suspensions, including saline and buffered bases. Examples of oils are oils of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil , Mineral oil, olive oil, sunflower oil, and cod liver oil. Parenteral vehicles (for subcutaneous, intravenous, intraarterial, or intramuscular injection) include sodium vaporized solution, Ringer's dextrose bran, Dextrose and sodium gas, lactated Ringer's solution and qualitative oil. Intravenous vehicles include liquid and nutrient supplements, electrolyte supplements such as Ringer 15 Dextrose as Examples include sterile liquids such as water and oil, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants. Generally, the preferred liquid carriers are water, saline, and dextrose in water Related to sugar solutions and aliphatic diols such as propylene glycol or 5 ^ ethanease, especially for injectable solutions. Examples of oils are petroleum, animal, vegetable or synthetic origin oils, such as peanut oil, Soybean oil, mineral oil, olive oil, sunflower oil and cod liver oil. In addition, the composition may additionally include binders such as gum arabic, corn starch, gelatin, carbomer, ethyl cellulose, guar Gum, hydroxypropyl fiber Cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone); 50 200526201 disintegrants (such as corn flour, potato flour, alginic acid, stone dioxide, cross-linked slow methylcellulose sodium salt , Cross-linked polyacetophenone, guar bean, dianfan light sodium acetate); buffers with a variety of pH and ionic strength (such as addition, deletion, acetate, phytate); additives such as albumin or Gelatin to avoid adsorption to the surface; detergents (such as Tween20, Tween80piuronic, bile salts); protease inhibitors: surfactants (such as sodium lauryl sulfate); penetration enhancers; solubilizers (such as acrylic Triol, Polyethylene Glycerol) · Antioxidants (such as ascorbic acid, sodium pyrosulfite, butylated benzyl alcohol; stabilizers (such as light propyl cellulose, propyl methyl cellulose ); Tackifiers (such as H) carbomer (―), colloidal silica, ethyl cellulose, guar sweeteners (such as Asparagus, phenylalanine, and thalassic acid); Preservatives (such as Thimerosai, benzyl alcohol, methyl or propyl p-hydroxybenzoate); Lubricants (such as stearic acid, magnesium stearate, polyethylene glycol, sodium lauryl sulfate) ·, glidants (such as colloidal silicon dioxide); plasticizers (such as diethyl benzene 15 gallate) Ester, triethyl citrate); emulsifiers (such as carbomer, hydroxypropyl cellulose, sodium lauryl sulfate); polymer coatings (such as poloxamer or poloxa) Poloxamine); coatings and film-forming agents (such as ethyl cellulose, acrylic acid, polymethyl acrylic acid); and / or adjuvants. 20 In another embodiment, the pharmaceutical composition provided herein is a controlled release composition, that is, the composition releases a compound during a period of time after administration. Controlled or sustained release compositions include formulations located in lipophilic reservoirs (such as fatty acids, waxes, oils). In another embodiment, the composition is an immediate-release composition, that is, the composition releases all SARM compounds immediately after administration. In another embodiment, the pharmaceutical composition can be delivered in a controlled release system. For example, the agent may be administered using intravenous infusion, implantable osmotic pumps, transdermal patches, liposomes, or other modes of administration. In a practical example, a 'pump can be used' (see the previous article by Langer; Sefton in CRC Crit · Ref. Biomed. Eng. No. 14 p. 201 (1987); Buchwald et al. In Surgery 88, p. 507 (1980); Saudek et al. N. Engl J. Med. 321, p. 574 (1989) b). In another embodiment, a polymerizable substance may be used. In another embodiment 10, 'a controlled release system can be placed near the target of treatment, that is, the brain, so that only a part of the systemic dose is needed (see, for example, Goodson in "Medical Applications of Controlled Release," Issue 2, pp. 115-138 (1984).) In a comprehensive review of Langer (Science, 249, 1527-1533 (1990)), other controlled release systems are addressed. 15 The The composition also includes the active substance in or on a granular formulation of a polymerizable compound such as polylactic acid, polyglycolic acid, hydrogel, or the like, or in liposomes, microemulsions, micelles, monolayers, or Multilayer carrier, red blood cell shadow or protoplast. These components will affect the physical state, solubility, stability, release rate in vivo and clearance rate in vivo. 20 The present invention also encompasses polymers such as Poirot Poloxamer or poloxamine-coated granular composition, coupled with antibodies, ligands, or antigens directed against tissue-specific receptors or coordinated with tissue-specific receptors Base coupling The present invention also covers water-soluble polymers such as polyethylene 52 200526201 alcohols, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyethylene, etc. Base. Compounds modified from rolidone or polyproline. The modified compounds are known to exhibit significantly longer half-life in blood after intravenous injection than the corresponding unmodified compounds 5 ( Abuchowski (1981); Newmark et al. (1981); and Katre et al. (1981). These modifications may also increase the solubility of the compound in aqueous solutions, eliminate aggregation, and improve the compound. Physical and chemical stability, and significantly reduce the immunogenicity and reactivity of the compound. As a result, the polymerized 10 adduct is administered at a lower frequency or lower dose than the unmodified compound To achieve the desired biological activity in vivo. The preparation of a pharmaceutical composition containing an active ingredient is well known in the art, such as by mixing, granulating or tabletting methods. Active treatment Servings are usually mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient. 15 For oral administration, SARM agents or physiologically tolerable derivatives such as salts, vinegars, N_oxidants And other additives commonly used for this purpose such as carriers, stabilizers or inert diluents, and by conventional methods into suitable dosage forms, such as lozenges; film-coated keys; hard or soft gelatin capsules; Alcoholic or oily solution. For parenteral administration, the SARM agent or its physiologically tolerable derivatives such as salts, vinegars, N-oxides, etc. are converted into a solution, suspension or Emulsions, if they are inflamed, add suitable substances, such as stabilizers or other substances. The active ingredient can be formulated in the form of neutral pharmaceutically acceptable salts. Pharmaceutically acceptable salts include acid addition salts (formed with free amine groups of multi-month or bean knives), formed with inorganic acids such as hydrochloric acid or lysine, or with organic acids such as acetic acid, oxalic acid , Tartaric acid, ^ phenyl ethyl 'and others. Salts derived from hybrid silk can also be derived from inorganic tests such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, hydrogen hydroxide or iron hydroxide, and from organic tests such as isopropylamine, trimethyl Aminoamine, tert-ethanol, histamine, procaine, etc. For commercial use, the salts of SARM will be pharmaceutically acceptable salts. However, other salts may be suitable for use in the preparation of the compound Lu 10 or a pharmaceutically acceptable salt thereof. Pharmaceutically acceptable members of the compounds of the present invention include acid addition salts, which can be obtained, for example, by combining the compounds of the present invention with pharmaceutically acceptable acids such as hydrochloric acid, sulfuric acid, methanesulfonic acid, A solution of one of trans-butenedioic acid, cis-butenedioic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, osmic acid, tartaric acid, carbonic acid, or phosphoric acid is mixed and formed. 15 As defined herein, "contacting" refers to introducing a SARM compound of the present invention into a sample containing the enzyme in a test tube, flask, tissue culture, wafer, array, plate, microplate, capillary tube, etc. And cultivate at a temperature for a period of time sufficient to allow SARM to bind to the enzyme. The method for contacting the sample with SARM or other specific binding components is known to skilled artisans 20 and may The selection is based on the type of analysis procedure to be performed. The cultivation method is also a standard method and known to skilled artisans. In another embodiment, the term "contact," refers to the introduction of a Sarm compound of the invention Of the individuals receiving treatment, the 811% of the compound was allowed to contact the androgen receptor in vivo. 54 200526201 As used herein, "treatment," -words, "prophylactic treatment, and therapeutic treatment of disorders." As used herein, the words "reduced ,,," depressed, "and" inhibited, "have general understanding Implications of mitigation or diminution. The term "progressive," as used herein, refers to the extent or severity of enlargement, progression, growth, or deterioration. The term "recurrence", as used in 5 10 15 20, refers to a disease after its remission. Relapse. As used herein, "administration," means the contact of a body with a SARM compound of the invention. As used herein, the administration can be accomplished in vitro, i.e. in a test tube, or in vivo, i.e. in a living organism such as a human cell or tissue. In the examples, the invention encompasses administering a compound of the invention to a subject. In one embodiment, SARM compounds for ingredients are also included in the invention including seeding as active. However, within the scope of the present invention, a method of treating and / or medulla-related disorders comprises administering a sarm compound and / or a combination of treatments. The # _ includes but is not limited to: LHRH debris, reversible anti-ozaki, anti-hybrid hormone, anti-cancer drugs, 5-alpha reductase inhibitors, aromatic ring invertase inhibitors, luteinizing hormones, and other hormones Pharmacologically active agents, selective estrogen receptor regulators (RM), lutein _, progesterone, pDE5 inhibitors, morphine dehydrate, bisphosphonates, and / or additional _arms. Thus, in the -Example, the method of the present invention comprises administering the selective androgen receptor modulator compound in combination with the -rh analog. In another embodiment, the method of the present invention comprises administering a selective male hormone receptor modulator compound and a selectable anti-heterohormone in combination. In another embodiment, the method of the present invention comprises combining a traitor-selective androgen 55 200526201 5 10 15 20 receptor modulator compound and an anti-estrogen. In another embodiment, the method includes administering a selective hormone receptor modulator and an anticancer drug in combination. In another embodiment, the method of the present invention includes iris administration—a selective androgen receptor modulator compound—a protoenzyme. In another implementation method, the method of the present invention includes a grade mouth and # Selective Androgen Receptor Regulator Compounds and Aromatic Production Transformation In another embodiment, the method of the present invention includes ^ two selective androgen receptor modulator compounds and the number of luteal bodies. "In another embodiment, the method of the present invention includes the combined administration of a hormone receptor Modulator compound and an agent via other cytogenetic effects. In another embodiment, the dagger of the present invention is administered in combination with a selective male hormone regulated by an It modulator compound and a selective estrogen receptor. (SERM). In another embodiment, the method includes a combination of selective male hormone receptor modulation = 4 and-progesterone. In another embodiment, the combination of prescription 7 of the present invention-selective Sexual androgenic hormones are affected by ganglion compounds and promiscuous hormones. In another embodiment, the method of the present invention includes the combination of administrating 14 androgen receptor modulator compounds with a species of PDE5, which are not inhibited by tune compounds and A dehydrated morphine. In one embodiment, the method of naming and demonstrating morphine includes administering a selective androgen receptor compound and a bisphosphonate in combination. In another embodiment, This post. '^ Includes a combination of Selective androgen receptor modulators and eight or more additional SARMs. Α 56 200526201 The following examples are provided to more fully illustrate the preferred embodiments of the present invention. However, they should not be waited for in any way. It is considered to limit the broad scope of the present invention. Detailed Experimental Part 5 First Example < | (ΒΜ〇 :) BMD minerals (BMD 彳 $ f 彡 胄) self-approved seller purchased 260 (260) Sprague-Dawley Rats (aged 23 weeks), and used in this experiment. _ 10 Animals were randomly assigned to each of the treatment groups (10 animals per group) listed below. Animals assigned to groups 6 to 26, Ovariectomy (OVX) was performed on the first day of the experiment. The drug administration effect of compound VI, compound IX and compound along, anti-androgen and / or DHT was performed immediately (that is, on the 15th day of removal of Chaotiantian) ) Or 90 days after ovariectomy to assess the ability of these compounds to inhibit the residual osteolytic effect (immediate treatment) or to stimulate bone formation (delayed treatment delay). The compounds were administered daily by subcutaneous injection (0.25 ml). The compounds under investigation were carried out to the 180th day of the experiment. Drug solutions were prepared daily by dissolving in ethanol and diluting with polyethylene glycol 300. Percent ethanol in all carriers 2 The ratios are all the same and measured based on the solubility of the test compound. The DEXA image is up to 丨 days after ovariectomy, and the month is shown in the table below. The bone mineral density (Bmd), bone mineral shellfish content (BMC), bone mineral area (BMA), and fat-free body weight were measured at each time point. (LBM), fat weight (FM), total body weight (TBM) and 57 200526201 subregional bone mineral density (BMD) of the lumbar spine and left femur. All animals were sacrificed on day 181. Femurs were excised from the sacrificed rats And tibia for follow-up experiments. Serum and urine samples were collected before or at the time of sacrifice, and the serum of osteocalcin, 5 IL-6, IGF_1 was determined for 5 animals in each group. Concentration and urine concentration of deoxypyridoline and creatinine.

〇 rYNHC0CH3

Delayed treatment of alpha group status (milligrams) Immediate treatment (mical white carotamide (mical kites) DHT ^ (millidays) — date of DEXA __ 1 complete-· one by one-〇, 30,60,90,120,150, __180 2 complete 10 (VI)-one 0,90,120,150,180 3 complete-10 (VI) 0,30,60,90 4 complete--10 0,90,120,150,180 5 complete---10 0,30, 60,90 6 Ovariectomy---10 > 30,60,90,120,150, 180 7 Ovariectomy 0.10 (VI)--0,90,120,150,180 8 Ovariectomy 0.30 (VI) One-0,90,120,150,180 9 Ovariectomy 0.50 (VI) One-to-one 0,90,120,150,180 10 Ovariectomy 0.75 (VI)------ 0,90,120,150,180 11 Ovariectomy 1.00 (VI)-One ----- 0,90,120,150,180 12 Ovariectomy 3.00 (VI)-One — 0,90,120,150,180 13 Ovariectomy-0.10 (VI)-One 0,30,60,90 14 Ovariectomy-0.30 (VI)------ —--- 0,30,60,90 58 200526201 Group State Delayed Treatment (mW days) 15 Ovariectomy-0.5C 16 Ovariectomy-0.75 17 Ovariectomy-1.0C 18 Ovariectomy-3.0C 19 Ovariectomy 0.5 (VI) 20 Ovariectomy-0.5 21 Ovariectomy-22 Ovariectomy-23 Ovariectomy 1.00 (IX) 24 Ovariectomy-1.00 25 Ovariectomy 1.00 (XI) 26 Ovariectomy-1.00 White Carrotamine ( Bicalutamide) (no exemption / day) DHT (no sound for 7 days) Date of DEXA 0,30,60,90 0,30,60,90 0,30,60,90 0,30,60,90 1.0 0, 90,120,150,180 0,30,60,90 0,30,60,90 0,90,120,150,180 0,90,120,150,180 0,30,60,90 0,90,120,150,180 0,30,60,90 Results »The results are shown in Table 1. The second case of this compound with a dose according to Xinxinfa and Zhibenfa_SARM compounds was b-gongli 0 bone mineral content (BMC) in rats. One hundred and eleven females were removed and one of the 1 to 811 treatment groups was excised. In experiments 1 to 6 groups were injected subcutaneously. Groups 9 to 11 are complete animals. The first dose of 13 mg / day received the combination: dihydropyridine (Dht) ^ Vi in the amounts of 0.3, 0.5, 0.5, 1.0, 10, respectively. Groups 7 and 11 received a 1 mg / day dose of the control group and the filled control group. Groups 9 and 9 were the resected and nested objects VI, respectively. All animals were treated with a dose of 1 (% α1.0 mg / day received combined mouth, 120 days. Dual energy X-ray absorptiometry (DEXA) was used on days 1, 30, 60, 90 and 120 59 200526201 Bone mineral content (BMC) was measured. Bone mineral content (BMC) in all groups treated with compound VI showed a time- and dose-dependent increase, observed in groups 1 to 6 from 5 to 22 · 9, respectively. , 26.0, 28.5, 30 · 5, 30.0, and 40.1%. At a dose of! Mg / day, DHT increased bone mineral content (BMC) by 15%. Compound VI inhibited osteolysis, and in this mode Its effectiveness is stronger than DHT. Skilled artisans will understand that the present invention is not limited to those specifically shown and described above. On the contrary, the scope of the present invention is defined by the scope of the following patent application ... C diagrams are simply explained 3 Figure 1: Effects of SARM on bone mineral content (BMC) and bone mineral density (BMD) in female rats undergoing ovariectomy. [Explanation of symbols of main components] (none) 60

Claims (1)

200526201 10. Scope of patent application: 1. A method for treating a subject having a bone-related disorder, the method comprising the step of administering to the individual a selective androgen receptor modulator (SARM) compound. 5 2. The method according to item 1 of the patent application scope, wherein the method comprises administering the SARM compound—analogue, derivative, isomer, metabolite, pharmaceutically acceptable salt, agent, hydrate or N-oxide, or any combination thereof. 3. If the scope of patent application is the first! The method of clause 1, wherein the osteoporosis-related disorder is 10 osteoporosis, osteoporosis, increased osteolytic effects, fractures, weak bones, reduced bone mineral density (BMD), or any combination thereof. 4. The method of claim 1 in the scope of the patent application, wherein the 5111111 compound is represented by a structure of formula I and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Accepted salts, medicaments, hydrates, N_I5 oxides, or any combination thereof: Where G is oxygen or sulfur; X is one-bond, oxygen, CH2, NH, selenium, PR, NO or clothing; T is OH, OR, -NHCOCH3 or NHCOR; 20 Z is N02, CN, COOH, COR, NHCOR Or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; 61 200526201 Q is alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS, OCN, NCO; or Q and the benzene ring to which it is connected is a compound of structural formula A, B or C The fused ring system represented R is alkyl, haloalkyl, di-i-alkyl, tri-alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, dilute or OH; and RACH3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3. 5. The method according to item 1 of the scope of patent application, wherein the SARM compound is a compound represented by the structure of Chemical Formula II and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable Salts, pharmaceuticals, hydrates, N-oxides or any combination thereof: II where X is a bond, oxygen, CH2, NH, Shixi, PR, NO or NR; Z is N02, CN, COOH, COR, NHCOR or CONHR; 62 200526201 Y is CF3, fluorine, iodine, bromine, gas , CN, CR3, or SnR3; Q is alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OC, OR 0S02R, S02R, SR, SCN, NCS, OCN, NCO; or Q and the benzene ring to which it is connected is a fused ring system represented by the structural formula A, B or C; R is an alkyl group, a substituted alkyl group, a dihalogenated alkyl group, a trisubstituted alkyl group, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or OH. 6. The method of claim 1 in which the compound is a compound represented by the structure having the formula III and / or its analog, 15 derivative, isomer, metabolite, pharmaceutically acceptable salt Class, agent, hydrate, N-oxide or any combination thereof: Rk T G is oxygen or sulfur; CH3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3; 63 200526201 T is OH, OR, -NHCOCH3 or NHCOR; R is alkyl, haloalkyl, dihaloalkyl, trifunctional alkyl, CH2F, CHF2, cf3, cf2cf3, aryl, phenyl, halogen, alkenyl or OH; 5 A is a ring selected from the group consisting of: γ B is a ring selected from the group: Where A and B cannot be a benzene ring at the same time; 10 Z is N02, CN, COOH, COR, NHC0R or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; Qi and Q2 are each independently For hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS, OCN, NCO, 64 15 200526201 Q3 and Q4 are independently hydrogen, alkyl, halogen, cf3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, nhcsrnhso2ch3, NHS02R, OR, COR , 50 ° COR, 0S02R, S02R or SR, SCN, NCS, OCN, NCO; Wi is oxygen, NH, NR, NO or sulfur; and W2 is nitrogen or NO. 7. The method according to item 1 of the scope of patent application, wherein the SARM compound is one of the compounds represented by the structure of Chemical Formula IV and / or its analogs, 10 derivatives, isomers, metabolites, pharmaceutically acceptable Salts, medicaments, hydrates, N-oxides or any combination thereof: Where X is a single bond, oxygen, CH2, NH, selenium, PR, NO or NR; G is oxygen or sulfur, 15 τ is 0H, OR, -NHCOCH3 or NHCOR; R is alkyl, haloalkyl, dihaloalkane Group, trihaloalkyl, CH2F, chf2, cf3, cf2cf3, aryl, phenyl, halogen, alkenyl or OH; R] is CH3, CH2F, chf2, CF3, CH2CH3 or CF2CF3; 20 R2 is fluorine, gas, bromine , Broken, CH3, CF3, OH, CN, No2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, 65 200526201 OR, NH2, NHR, NR2, SR, SCN, NCS, OCN, NCO; R3 Is fluorine, chlorine, bromine, iodine, CN, N02, COR, COOH, CONHR, CF3, SnR3; or R3 and the benzene ring to which it is connected form a fused ring system represented by the following structural formula; Or 2 5 Y Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, gas, iodine, CN or SnR3; Q is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, 10 NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OH, OR, COR, OCOR, OS〇2: R, 〇2R, SR; or Q and the benzene ring to which it is connected is a thick one represented by structural formula A, B or C Ring system 15 11 is an integer from 1 to 4; and m is an integer from 1 to 3. 8 · If the patent scope is declared! The method of claim 1, wherein the intestinal compound is a compound represented by the structure of Formula V and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable salts, agents, 20 Hydrate, N · oxide or any combination thereof: 66 200526201 V where 5 R2 is fluorine, chlorine, bromine, angstrom, CH3, CF3, OH, CN, N02, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR; R3 is fluorine , Gas, bromine, polonium, CN, N02, COR, COOH, CONHR, CF3, SnR3; or R3 and the benzene ring to which it is connected form a fused ring system represented by the following structural formula; 10 15 R is alkyl, functional alkyl, dihaloalkyl, tri-alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or OH; Z is N02, CN, COR COOH or CONHR; Y is CF3, fluorine, bromine, gas, hydrogen, CN or SnR3; Q is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OH, OR, COR, OCOR, OS〇2R, S〇2R, SR; or Q and the benzene ring to which it is attached are a 67 200526201 Representative fused ring system; η is an integer from 1 to 4; and m is an integer from 1 to 3. 5 9 · The method according to item 1 of the scope of patent application, wherein the SAR compound is a compound represented by the structure of Chemical Formula VI and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable Accepted salts, agents, hydrates, N-oxides or any combination thereof: 10 10 · The method according to item 1 of the scope of patent application, wherein the SAR compound is a compound represented by the structure of Chemical Formula VII and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Accepted salts, agents, hydrates, N-oxides, or any combination thereof: 15 11. The method according to item 1 of the scope of patent application, wherein the SARM compound is a compound represented by the structure having the formula VIII and / or its analogue 68 200526201 Compound, derivative, isomer, metabolite, Acceptable salts, hydrates, N-oxides, or any combination thereof: In the method as described in the scope of patent application, the rm compound is represented by the structure of five chemical families IX—compounds and / or their analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, pharmaceuticals, hydrates, N-oxides or any combination thereof: 3. Rushen # patent method, the compound is represented by a structure having the chemical formula X—compound and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable Salts, pharmaceuticals, hydrates, N-oxides or any combination thereof: Method, wherein the compound is represented by the structure of Chemical Formula XI-compounds and / or its analogs, N-oxide or any combination thereof: " 15 · If applying for the patent of 4 | Please refer to the method of item 丨, wherein the § a R M is a male 5 hormone receptor equivalent. 16. The method of claim ㈣ item 丨, wherein the face is a male hormone receptor antagonist. 17. The oldest method in the scope of the patent application, wherein the administration effect comprises the administration of a pharmaceutical composition, which comprises the SARM and / or its analogues, derivative 10, isomers, metabolites, pharmaceutically acceptable Salt, medicament, spout N-oxide or any combination thereof; and a pharmaceutically acceptable carrier. 18. The method of claim 17 in which the scope of patent application, wherein the effect of administration comprises intravenously or intramuscularly injecting the musculature in a liquid form to the individual; implanting the pharmaceutical subcutaneously in the individual contains the pharmaceutical System A ^ 丨, the method of orally administering liquid X or drug X to the complement or topically applying the method of Shinyue Concentration ® Item 17 on the skin surface of the individual, wherein the pharmaceutical preparation is a pill ,-A lozenge, a capsule, a solution, a suspension, an emulsion, a _ agent, a gel, a cream, a suppository 70 20 200526201 or a parenteral formula. 20. The method of claim 1 in which the individual is a male individual. 21. The method of claim 1 in which the subject is an aging 5 male subject. 22. The method of claim 1 in which the individual is a female individual. 23. The method of claim 1 in which the subject is an aging female subject. 10 24 · —A method for preventing, suppressing, inhibiting or reducing the incidence of a bone-related disorder in a body, the method comprising administering to the individual a selective androgen step. 25. The method of claim 24, wherein the method comprises administering a hydrazone analog, a contact substance, an isomer, a metabolite, an acceptable salt, a medicament, a hydrate, or a hydrazone of the SARM compound. N · oxide, or any combination thereof. 26. The method of claim 24, wherein the osteogenesis-related disorder is osteoporosis, osteopenia, increased osteolysis, fractures, weak bone pathways, reduced bone mineral density (BMD), or any of them combination. 2027. The method of claim 24, wherein the SARM compound is represented by the structure of Chemical Formula 1 and / or its analogs, derivatives, isomers, pharmaceutically acceptable salts Class, medicament, hydrate, N-oxide or any combination thereof: 71 200526201 Where G is oxygen or sulfur; X is one-bond, oxygen, CH2, NH, selenium, PR, NO or NR; T is OH, OR, -NHCOCH3 or NHCOR; 5 Z is N02, CN, COOH, COR, NHCOR Or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; Q is alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3 , 10 NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS v OCN, NCO; or Q and the benzene ring to which it is connected is a condensed ring represented by structural formula A, B or C system; 15 R is alkyl, arylalkyl, dialkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or OH; and R ^ CH3, CH2F, CHF2 , CF3, CH2CH3 or CF2CF3 〇28 · As in the method of claim 24, wherein the SARM compound is 72 200526201 one of the compounds represented by the structure of the chemical formula π and / or its analogs, derivatives, isomers , Metabolites, pharmaceutically acceptable salts, agents, hydrates, N-oxides, or any combination thereof: II 5 where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; Z is No. 02, CN, C00H, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine , CN, CR3 or SnR3; Q is the hospital base, halogen, CF3, CNCR3, SnR3, NR2, NHCOCHs, NHCOCF3, NHCOR, NHCONHR, 10 NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OC , 0S02R, S02R, SR, SCN, NCS, OCN, NCO; or Q together with the benzene ring to which it is connected is a fused ring system represented by the structural formula A, B or C; R is an alkyl group, an alkyl group, a di-alkyl group, a tri-alkyl group, a CH2-F, chf2, cf3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH. 29. The method according to claim 24, wherein the SARM compound is 73 200526201. One of the compounds represented by the structure having the formula III and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Accepted salts, medicaments, hydrates, N-oxides or any combination thereof: Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; G is oxygen or sulfur; RACH3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3; T is OH, OR, -NHCOCH3 or NHCOR; 10 R is alkyl, i-alkyl, di-i-alkyl, tri-i-alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH; A is selected from the group Middle ring: B is a ring selected from the group: Where A and B cannot be a benzene ring at the same time; 74 200526201 Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 or SnR3; (^ and (32 Each independently is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, 5 NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R, SR, SCN, NCS, OCN, NCO, Q3 and Q4 are each independently hydrogen, alkyl, halogen, cf3, cncr3, 10 15 SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R or SR, SCN, NCS, OCN, NCO; Wi is oxygen, NH, NR, NO or sulfur; and W2 is nitrogen or NO. 30. The method of claim 24, wherein the SARM compound is a compound represented by the structure of Chemical Formula IV and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, pharmaceuticals, hydrates, N-oxides or any combination thereof: 75 200526201 where X is a single bond, oxygen, CH2, NH, selenium, PR, NO or NR; G is oxygen or sulfur; T is OH, OR, _NHCOCH3 or NHCOR; R is an alkyl group, a halogenated alkyl group, Di-halo, trihalo, 5 ch2f, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or OH; Ri is ch3, CH2F, CHF2, CF3, CH2CH3, or CF2CF3; R2 is Fluorine, chlorine, bromine, iodine, CH3, CF3, OH, CN, N02, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, 100-R, NH2, NHR, NR2, SR, SCN, NCS, OCN, NCO; R3 is fluorine, chlorine, bromine, iodine, CN, N02, COR, COOH, CONHR, CF3, SnR3; or R3 and the benzene ring connected to it form a fused ring system represented by the following structural formula; Or Υ 15 / is ·, CN, COR, COOH, or CONHR; Y is CF3, alkyl, halogen, chloro, e, CN or SnR3; Q is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3 , NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, 20 NHCSRNHS〇2CH3, NHS02R, OH, OR, COR, OCOR, 0S02R, S02R, SR; or Q and the benzene ring to which it is connected are one Condensed ring system represented by structural formula A, B or C; 76 200526201 η is an integer from 1 to 4; and m is an integer from 1 to 3. 31. The method of claim 24, wherein the SAR] VHb compound is a compound and / or its analogs, derivatives, isomers, metabolites, Acceptable salts, agents, hydrates, N-oxides or any combination thereof: 10 R2 is fluorine, gas, bromine, iodine, CH3, CF3, OH, CN, N02, NHCOCH3, NHCOCF3, NHCOR, alkyl, aryl radical, OR, NH2, NHR, NR2, SR; R3 is fluorine, gas , Bromine, iodine, CN, N02, coon, CONHR, CF3, S11R3; or & together with the benzene ring to which they are attached, form a fused ring system represented by the following structural formula; R is alkyl, substituted alkyl, di-substituted alkyl, tri-substituted alkyl, 200526201 CH2F, CHF2, cf3, cf2cf3, aryl, phenyl, halogen, alkenyl, or OH; Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, gas, iodine, CN or SnR3; 5 Q is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, 0H, OR, COR, OCOR, 0S02R, S02R, SR; or Q and the benzene ring to which it is connected are a 0 represented by the formula A, B or c Fused ring system A B C η is an integer from 1 to 4; and m is an integer from 1 to 3. 32. The method of claim 24, wherein the SARM compound is represented by a compound represented by the structure represented by formula VI: a compound and / or its analogs, derivatives, isomers, metabolites, pharmaceuticals Acceptable salts, agents, hydrates, N_oxides or any combination thereof: 33. The method of applying for patent No. 4 item, wherein the compound compound 78 200526201 is one of the compounds represented by the structure having the chemical formula VII and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Accepted salts, agents, hydrates, N-oxides or any combination thereof: 5 34. The method according to claim 24, wherein the SARM compound is a compound represented by the structure having the formula VIII and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, medicaments, hydrates, N-oxides or any combination thereof: 10 35. The method according to claim 24, wherein the SARM compound is one of the compounds represented by the structure of Chemical Formula IX and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, medicaments, hydrates, N-oxides or any combination thereof: 15 36. The method according to item 24 of the application for a patent, wherein the SARM compound is 79 200526201: represented by a structure having a formula of x—compounds and / or its similar bioisomers, metabolites, Acceptable salts, hydrazones, hydrates, N-oxides, or any combination thereof: 5 37 • The method in item 24 of the patent scope, wherein the SARM compound is 2 compounds represented by the structure of Chemical Formula XI-compounds and / or the like, : 10 38. The method according to item 24 of the patent application, wherein fiber making is an androgen receptor synergist. 39. The method according to the scope of patent application, wherein the M · is an androgen receptor antagonist. [The method of item 24 in the scope of claim 5, wherein the administration includes administration of a pharmaceutical composition containing the SARM and / or its analogs, derivatives, isomers, metabolites, Accepted salts, medicaments, water, N-oxides, or any combination thereof; and a pharmaceutically acceptable carrier. 80 200526201 41. The method of claim 40, wherein the administration comprises injecting the pharmaceutical preparation in a liquid form intravenously, intra-arterially or intramuscularly to the individual; One pill of the pharmaceutical preparation; the liquid or solid form 5 of the pharmaceutical preparation is administered orally to the individual; or the pharmaceutical preparation is administered topically on the skin surface of the individual. 42. The method of claim 40, wherein the pharmaceutical preparation is a pill, a lozenge, a capsule, a solution, a suspension, an emulsion, a brew, a gel, a cream, A 10-dose test or a parenteral formula. 43. The method of claim 24, wherein the individual is a male individual. 44. The method of claim 24, wherein the individual is an aging male individual. 15 45. The method of claim 24, wherein the individual is a female individual. 46. The method of claim 24, wherein the individual is an aging female individual. 47. A method of treating an individual suffering from osteoporosis, osteoporosis, an increase in osteolytic effect, fractures, weak bones, reduced bone mineral density (BMD), or any combination thereof, the method comprising The subject is administered a step of a selective androgen receptor modulator (SARM) compound. 48. The method of claim 47, wherein the method includes administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, agent, hydrate of the 81 200526201 SARM compound Or N_oxide, or any combination thereof. 49. The method according to claim 47, wherein the SARM compound is represented by the structure of Formula I and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable salts, Agent, hydrate, N-oxide or any combination thereof: Where G is oxygen or sulfur; 10 15 X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; T is OH, OR, -NHCOCH3 or NHCOR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 or SnR3; Q is alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, 〇S02R, S02R, SR, SCN, NCS, OCN, NCO; or Q together with the benzene ring to which it is connected is a fused ring system represented by structural formula A, B or C; 82 20 200526201 ABCR is alkyl, alkynyl, di-alkyl, trihaloalkyl, CH2F, chf2, CFs, CF2CF3'aryl, phenyl, halogen, amyl or OH; and Ri is ch3, CH2F, CHF2, cf3, CH2CH3, or CF2CF3. 50. The method according to item 47 of the application for a patent, wherein the excitant is a compound represented by the structure of formula II and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Accepted salts, agents, hydrates, N-oxides, or any combination thereof: 10 II where X is a bond, oxygen, CH2, NH, Shixi, PR, NO or NR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, gas , CN, CR3 or SnR3; Q is alkyl, halogen, CF3, CNCR3, SnR3, NR2, 15 NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OC , 〇S02R, S02R, SR, SCN, NCS, OCN, NCO; or Q and its connected benzene ring is a 83 200526201 fused ring system represented by the structural formula A, B or C; R is alkyl, i-alkyl, di-alkyl, tri-i alkyl, ch2f, chf2, cf3, cf2cf3, aryl, phenyl, halogen, alkenyl 5 or OH. 51. The method according to claim 47, wherein the SARM compound is a compound represented by the structure having the formula III and / or its analog, derivative, isomer, metabolite, Salts, pharmaceuticals, hydrates, N-oxides or any combination thereof: 10 111 where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; G is oxygen or sulfur; RACH3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3; T is OH, OR, -NHCOCH3 or NHCOR; 15 R is alkyl, i-alkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH; A is selected from the group consisting of One ring: 84 200526201 γ B is a ring selected from the group consisting of: and Q: Where A and B cannot be a benzene ring at the same time; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; 10 Qi and Q2 each Independently hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R, SR, SCN, NCS, OCN, NCO, Q3 and Q4 are each independently hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R or SR, SCN, NCS, OCN, NCO; 85 15 200526201 Wi is oxygen, NH, NR, NO or sulfur; and W2 is nitrogen or NO. 52. The method according to item 47 of the patent application, wherein the SARM compound is a compound represented by the structure of Chemical Formula IV and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, agents, hydrates, N-oxides or any combination thereof: Where X is a bond, oxygen, CH2, NH, Shixi, PR, NO, or NR; G is oxygen or sulfur; ίο T is OH, OR, -NHCOCH3 or NHCOR; R is alkyl, _alkyl, Di-alkyl, tri! | Alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, fluorenyl, or OH; R! Is CH3, CH2F, chf2, cf3, ch2ch3, or CF2CF3; 15 R2 is fluorine, chlorine, bromine, polonium, CH3, CF3, OH, CN, N02, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR, SCN, NCS, OCN, NCO; R3 is Dun, Qi, Mo, E, CN, No2, COR, COOH, CONHR, CF3, SnR3; or Rs together with the benzene ring to which it is attached form a thickened one represented by the following structural formula: Ring system; 86 200526201 Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, desert, gas, carbon, CN or SnR3; Q is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, 5 NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OH, OR, COR, OCOR, OS〇2R, S〇2R, SR; or Q together with the benzene ring to which it is connected is a compound of formula A, B or The fused ring system represented by C; η is an integer from 1 to 4; and m is an integer from 1 to 3. 10 A B C 53 · Shishen, the method of patent No. 47, wherein the compound is one of the compounds represented by the structure having the chemical formula V and / or its analogues # bioisomers, metabolites, pharmaceutically acceptable Salts, medicaments, hydrates, N_oxides or any combination thereof: V 87 200526201 where R2 is fluorine, chlorine, > odor, arsenic, CH3, CF3, OH, CN, No2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2 SR; R3 is rat, gas, desert, carbon, CN, N02, COR, COOH, CONHR, CF3, SnR3; or R3 and the benzene ring connected to it form a condensed ring system represented by the following structural formula; Or 1 R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, 10 ch2f, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH; Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, gas, iodine, CN or SnR3; Q is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, 15 NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OH, OR, COR, OCOR, 0S02R, S02R, SR; or Q and the benzene ring to which it is connected is a fused ring system represented by structural formula A, B or C; 88 20 200526201 η is an integer from 1 to 4; and m is an integer from 1 to 3. 54. The method according to claim 47, wherein the SARM compound is a compound represented by the structure of Chemical Formula VI and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, medicaments, hydrates, N-oxides or any combination thereof: 55. The method of claim 47, wherein the SARM compound is one of the compounds represented by the structure of Chemical Formula VII and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, medicaments, hydrates, N-oxides or any combination thereof: 56. The method according to claim 47, wherein the SARM compound is one of the compounds represented by the structure of Chemical Formula VIII and / or its analogs 15 Salts, agents, hydrates, N-oxides or any combination thereof: 89 200526201 57. The method of claim 47, wherein the SARM compound is one of the compounds represented by the structure of Chemical Formula IX and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, 5 agents, hydrates, N-oxides or any combination thereof: 58. The method of claim 47, wherein the SARM compound is a compound represented by the structure having the chemical formula X and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, 10 agents, hydrates, N-oxides or any combination thereof: 59. The method according to claim 47, wherein the SARM compound is a compound represented by the structure of Chemical Formula XI and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, 15 agents, hydrates, N-oxides or any combination thereof: 90 200526201 60. The method of claim 47, wherein the SARM is an androgen receptor synergist. 61. The method of claim 47, wherein the SARM is a male sex hormone receptor antagonist. 62. The method of claim 47, wherein the administration includes administering a pharmaceutical composition comprising the SARM and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, medicaments, hydrates, N-oxides, or any combination thereof; and a pharmaceutically acceptable carrier. 63. The method of claim 62, wherein the administration includes injecting the pharmaceutical preparation in a liquid form intravenously, intraarterially or intramuscularly to the individual; implanting the pharmaceutical containing the pharmaceutical subcutaneously in the individual One pill of the preparation; the pharmaceutical preparation in liquid or solid form 15 is administered orally to the individual; or the pharmaceutical preparation is administered topically on the skin surface of the individual. 64. The method of claim 62, wherein the pharmaceutical preparation is a pill, a lozenge, a capsule, a solution, a suspension, an emulsion, a gallbladder, a gel, a cream, 20 suppositories or a parenteral formula. 65. The method of claim 47, wherein the individual is a male 91 200526201. 66. The method of claim 47, wherein the individual is an aging male individual. 67. The method according to item 47 of the patent application, wherein the individual is a female individual. 68 ' The method of claim 47, wherein the individual is an aging female individual. 69 ·-Prevent, suppress, suppress or reduce osteoporosis, osteoporosis, increased osteolytic effects, fractures, weak bones, reduced bone mineral density (BMD), or any combination thereof in individuals Method of rate'The method includes the step of administering to the individual a selective androgen receptor modulator (SARM) compound. 70. The method of claim 69, wherein the method comprises administering an analog, derivative, isomer, metabolite, 15 pharmaceutically acceptable salt, agent, hydrate or N-oxide, or any combination thereof. 71. The method according to claim 69, wherein the SArm compound is represented by a structure having Chemical Formula I and / or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt thereof, Agent, hydrate, 20 N-oxide or any combination thereof: Z 92 200526201 where G is oxygen or sulfur; X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; T is OH, OR, -NHCOCH3 or NHCOR; Z is N02, CN, COOH, COR, NHCOR or CONHR; 5 Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; Q is alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, 100S02R, S02R, SR , SCN, NCS, OCN, NCO; or Q together with the benzene ring to which it is connected is a dense system represented by structural formula A, B or C, R is an alkyl group, a substituted alkyl group, a substituted dialkyl group, a substituted trialkyl group, 15 CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or OH; and Ri is ch3, ch2f, chf2, cf3, ch2ch3, or cf2cf3. 72. The method according to claim 69, wherein the compound is one of the compounds represented by the structure having the chemical formula II and / or its analog 20, derivative, isomer, metabolite, pharmaceutically acceptable salt Class, medicament, hydrate, N-oxide or any combination thereof: 93 200526201 Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 Or SnR3; 5 Q is alkyl, halogen, CF3, CNCR3, SnR3, NR2 NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS, OCN, NCO; or Q and its connected The benzene ring together is a fused ring system represented by the structural formula A, B or C; 15 〇 A R is alkyl, ch2f, chf2, or OH. Functional alkynyl, di-alkyl, tri-alkyl, CF3, CF2CF3, aryl, phenyl, functional element, dilute / synthetic group, this SARMization: structure with Γ academic formula m Represented-compounds and / or organisms, isomers, metabolites, pharmaceutically acceptable agents, hydrates, N-oxygen t-lice compounds or any combination thereof 94 200526201 Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; G is oxygen or sulfur; 5 RACH3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3; T is OH, OR, -NHCOCH3 or NHCOR ; R is an alkyl group, an alkyl group, an alkyl group, a trivalent group, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or OH; A is selected from the group One ring: 10 B is a ring selected from the group: Where A and B cannot be a benzene ring at the same time; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 or SnR3; (^ and (^ 2 each Independently hydrogen, alkyl, halogen, CF3, CNCR3, 95 15 200526201 SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, nhcsrnhso2ch3, NHS02R, OR, COR, OCOR, OS02R , S02R, SR, SCN, NCS, OCN, NCO, Q3 and Q4 are each independently hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OR, COR, 10 OCOR , 0S02R, S02R or SR, SCN, NCS, OCN, NCO; is oxygen, NH, NR, NO or sulfur; and W2 is said or NO. 74. The method according to claim 69, wherein the SARM compound is a compound represented by the structure of Chemical Formula IV and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, medicaments, hydrates, N-oxides or any combination thereof: Where X is a bond, oxygen, CH2, NH, stone, PR, NO or NR; G is oxygen or sulfur; 20 T is 0H, OR, -NHCOCH3 or NHCOR; 96 200526201 R is alkyl, haloalkyl , Di! I-alkyl, tri-alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, dilute or OH; RACH3, CH2F, chf2, cf3, ch2ch3 or cf2cf3; 5 R2 is Fluorine, chlorine, bromine, hydrogen, CH3, CF3, OH, CN, N02, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR, SCN, NCS, OCN, NCO; R3 is fluorine, gas, bromine, iodine, CN, N02, COR, COOH, CONHR, CF3, SnR3; or R3 and the benzene ring to which it is connected form 10 a fused ring system represented by the following structural formula; 〇 2 YZ is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, chlorine, iodine, CN or SnR3; Q is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, 15 NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHS02CH3, NHS02R, OH, OR, COR, OCOR, OSO # 'S〇2: R' SR; or Q and the benzene ring connected to it are one Fused ring system represented by structural formula A, B or C; 97 200526201 n is an integer from 1 to 4; and m is an integer from 1 to 3. 75. The method according to item 69 of the application for a patent, wherein the reading compound is a compound represented by the structure having the formula V and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable Salts, medicaments, hydrates, N-oxides or any combination thereof: R2 is Tun, Qi, Mo, Ai, CH3, CF3, OH, CN, No2, 10 NHCOCH3, NHCOCF3, NHCOR, Carbo, Aryl, OR, NH2, NHR, NR2, SR; R3 is fluorine , Gas, bromine, polonium, CN, N02, COR, COOH, CONHR 'CF3 >SnR3; or R3 and the benzene ring to which it is connected form a fused ring system represented by the following structural formula; R is an alkyl group, a 1-substituted alkyl group, a dihalogenated alkyl group, a trifunctional alkyl group, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or OH; Z is N02, CN, COR , COOH or CONHR; 98 200526201 Y is CF3, fluorine, bromine, chlorine, iodine, CN or SnR3; Q is hydrogen, alkyl, halogen, CF3, CNCR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, 5 NHCSRNHS02CH3, NHS02R, OH, OR, COR, OCOR, OS〇2R, S〇2R, SR; or Q together with the benzene ring to which it is connected is a compound of structural formula A, B or C Representative fused ring system; 10 A B C η is an integer from 1 to 4; and m is an integer from 1 to 3. 76. The method according to claim 69, wherein the SAR] yHb compound is a compound represented by the structure of Formula VI and / or its analogs, derivatives, isomers, metabolites, pharmacologically Acceptable salts, agents, hydrates, N-oxides or any combination thereof: 15 VI 〇77. The method of claim 69, wherein the SARM compound is represented by the structure of Chemical Formula VII—the compound and / or its analog derivative, isomer, metabolite, pharmacy Acceptable salts, agents, hydrates, N-oxides or any combination thereof: 200526201 78. The method according to claim 69, wherein the SARM compound is a compound represented by the structure of Chemical Formula VIII and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, 5 agents, hydrates, N-oxides or any combination thereof: 79. The method according to claim 69, wherein the SARM compound is a compound represented by the structure of Chemical Formula IX and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, 10 agents, hydrates, N-oxides or any combination thereof: 80. The method according to claim 69, wherein the SARM compound is a compound represented by the structure having the chemical formula X and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, 15 agents, hydrates, N-oxides or any combination thereof: 100 200526201 81. The method according to item 69 of the application, wherein the SARM compound is a compound represented by the structure of Chemical Formula XI and / or its analogs, derivatives, isomers, metabolites, pharmaceutically acceptable Salts, pharmaceuticals, hydrates, N-oxides or any combination thereof: NC cf3 XI CI 82. The method according to item 69 of the patent application, wherein the SARM is an androgen receptor synergist. 83. The method of claim 69, wherein the SARM is a male sex hormone receptor antagonist. 84. The method according to claim 69, wherein the administration includes administering a pharmaceutical composition comprising the SARM & / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable Salts, medicaments, hydrates, N-oxides or any combination thereof; and a pharmaceutically acceptable carrier. 85. A method as claimed in claim 84, wherein the administration comprises injecting the pharmaceutical preparation in a liquid form intra-pulsely, intra-arterially or intramuscularly to the individual; implanting the pharmaceutical subcutaneously in the individual contains the pharmaceutical One pill of the preparation 101 200526201; the liquid or solid form of the pharmaceutical preparation is administered orally to the individual; or the pharmaceutical preparation is administered topically on the skin surface of the individual. 86. The method as claimed in claim 84, wherein the pharmaceutical preparation is a 5 pills, a bond, a capsule, a solution, a suspension, an emulsion, a brew, a gel, a cream , A suppository or a parenteral formula. 87. The method of claim 69, wherein the individual is a male individual. 10 88. The method of claim 69, wherein the individual is an aging male individual. 89. The method of claim 69, wherein the individual is a female individual. 90. The method of claim 69, wherein the individual is an aging 15 female individual. 102